liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Sun, Xiao-Feng
Alternative names
Publications (10 of 175) Show all publications
Gnosa, S., Capodanno, A., Dahl Ejby Jensen, L. & Sun, X.-F. (2016). AEG-1 knockdown in colon cancer cell lines inhibits radiation-enhanced migration and invasion in vitro and in a novel in vivo zebrafish model. OncoTarget, 7(49), 81634-81644.
Open this publication in new window or tab >>AEG-1 knockdown in colon cancer cell lines inhibits radiation-enhanced migration and invasion in vitro and in a novel in vivo zebrafish model
2016 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 7, no 49, 81634-81644 p.Article in journal (Refereed) Published
Abstract [en]

Background Radiotherapy is a well-established anti-cancer treatment. Although radiotherapy has been shown to significantly decrease the local relapse in rectal cancer patients, the rate of distant metastasis is still very high. Several studies have shown that radiation enhances migration and invasion both in vitro and in vivo. The aim of this study was to evaluate whether AEG-1 is involved in radiation-enhanced migration and invasion in vitro and in a novel in vivo zebrafish model.

Materials and Methods We evaluated the involvement of AEG-1 in migration and invasion and radiation-enhanced migration and invasion by Boyden chamber assay in three colon cancer cell lines and respective AEG-1 knockdown cell lines. Furthermore, we injected the cells in zebrafish embryos and evaluated the amount of disseminated cells into the tail.

Results Migration and invasion was decreased in all the AEG-1 knockdown cell lines. Furthermore, radiation enhanced migration and invasion, while AEG-1 knockdown could abolish this effect. The results from the zebrafish model confirmed the results obtained in vitro. MMP-9 secretion and expression were decreased in AEG-1 knockdown cells.

Conclusion Our results demonstrate that AEG-1 knockdown inhibits migration and invasion, as well as radiation-enhanced migration and invasion. We speculate that this is done via the downregulation of the intrinsic or radiation-enhanced MMP-9 expression. The zebrafish model can be used to study early events in radiation-enhanced invasion.

Place, publisher, year, edition, pages
Impact Journals, 2016
Keyword
AEG-1, MTDH, LYRIC, Colon cancer, Zebrafish, Transwell migration and invasion, Radiation
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-121866 (URN)10.18632/oncotarget.13155 (DOI)000389877500121 ()27835571 (PubMedID)
Note

The previous status of this publication was manuscript

Funding agencies: Swedish Cancer Foundation; Swedish Research Council; Health Research Council in South-East Sweden; Onkologiska klinikernas i Linkoping

Available from: 2015-10-12 Created: 2015-10-12 Last updated: 2017-12-01Bibliographically approved
Li, Y., Zhang, X., Ge, J., Liu, X., Xu, S., Zhu, Z., . . . Sun, X.-F. (2016). Can Nup88 expression be associated with atypical endometrial hyperplasia and endometrial cancer? A preliminary study. Pathology, Research and Practice, 212(4), 274-278.
Open this publication in new window or tab >>Can Nup88 expression be associated with atypical endometrial hyperplasia and endometrial cancer? A preliminary study
Show others...
2016 (English)In: Pathology, Research and Practice, ISSN 0344-0338, E-ISSN 1618-0631, Vol. 212, no 4, 274-278 p.Article in journal (Refereed) Published
Abstract [en]

Background: Nup88 is overexpressed in a number of types of carcinomas and is associated with myometrial invasion, but its exact expression pattern in endometrial cancer and premalignant lesions is unknown. Aims: To evaluate the role of Nup88 in endometrial cancers and atypical endometrial hyperplasia and its clinicopathological significance. Methods: Nup88 expression was examined by immunohistochemistry in samples from 104 endometrial cancers, 21 atypical endometrial hyperplasia lesions, and 40 normal endometria. All samples were from patients who underwent surgery at the First Hospital of Hebei Medical University (Shijiazhuang, China) between April 2006 and December 2009. Nup88 expression was compared between the groups and associations were assessed between Nup88 and clinicopathological characteristics of the subjects. Results: Nup88 expression in cancer (76% of samples) and atypical hyperplasia (91%) was significantly higher compared to normal endometrium (33%, both P < 0.001), but there was no significant difference between endometrial cancer and atypical hyperplasia (P = 0.237). The expression of Nup88 increased significantly with increasing exposure time to estrogen (P = 0.033). Conclusions: Nup88 may be related to the occurrence of endometrial cancers and premalignant lesions. Nup88 might be a useful biomarker for pre-malignant lesions and early-stage endometrial cancer. (C) 2016 Elsevier GmbH. All rights reserved.

Place, publisher, year, edition, pages
ELSEVIER GMBH, URBAN & FISCHER VERLAG, 2016
Keyword
Nup88; Nuclear pore complexes; Endometrial cancer; Atypical endometrial hyperplasia; Immunohistochemistry; Biomarker
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-128983 (URN)10.1016/j.prp.2016.01.003 (DOI)000375500300006 ()26839161 (PubMedID)
Note

Funding Agencies|Natural Science Foundation General Program of Hebei Province [H2012206040]

Available from: 2016-06-09 Created: 2016-06-07 Last updated: 2017-11-30
Gnosa, S., Ticha, I., Haapaniemi, S. & Sun, X.-F. (2016). MTDH genetic variants in colorectal cancer patients. Scientific Reports, 6.
Open this publication in new window or tab >>MTDH genetic variants in colorectal cancer patients
2016 (English)In: Scientific Reports, ISSN 2045-2322, E-ISSN 2045-2322, Vol. 6Article in journal (Refereed) Published
Abstract [en]

Colorectal cancer (CRC) is the second most common cancer worldwide and accounts for around 8.5% of all cancer related death. The colorectal carcinogenesis is a complex process of genetic alterations. For better prognosis it is very important to understand the composition of genetic alterations in a tumor. Astrocyte elevated gene-1 (AEG-1) has been shown to be overexpressed in CRC and had prognostic significance. The aim of this study was to determine the frequency and the spectrum of MTDH variants, and their relationship to clinicopathological variables in CRC patients. The study included tumors from 356 unselected CRC patients. Mutation analysis of the MTDH gene, including coding region and adjacent intronic sequences, was performed by direct DNA sequencing. We detected 42 intronic variants, whereby 25 were novel. Furthermore, we found eight exonic variants of which four, one missense (c.977C>G) and three frameshift mutations (c.533delA, c.1731delA, c.1340dupA), were novel. In silico prediction analyses revealed that four variants c.232G>T, c.533delA, c.1340dupA and c.1731delA were deleterious. There were no correlations between the MTDH variants and tumor stage, differentiation or patient survival. The detection of pathogenic mutations and alterations in functional protein domains suggest their involvement in tumorigenesis, although none of the variants had prognostic potential.

Place, publisher, year, edition, pages
Nature Publishing Group, 2016
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-121865 (URN)10.1038/srep23163 (DOI)000372164500001 ()
Note

Funding agencies:  Swedish Cancer Foundation; Swedish Research Council, and the Health Research Council in South-East Sweden; Ministry of Health, Czech Republic [RVO 64165]

Vid tiden för disputation förelåg publikationen som manuskript

Available from: 2015-10-12 Created: 2015-10-12 Last updated: 2017-12-01Bibliographically approved
Liu, Y., Zhou, D., Long, F.-W., Chen, K.-L., Yang, H.-W., Lv, Z.-Y., . . . Zhou, Z.-G. (2016). Resolvin D1 protects against inflammation in experimental acute pancreatitis and associated lung injury. American Journal of Physiology - Gastrointestinal and Liver Physiology, 310(5), G303-G309.
Open this publication in new window or tab >>Resolvin D1 protects against inflammation in experimental acute pancreatitis and associated lung injury
Show others...
2016 (English)In: American Journal of Physiology - Gastrointestinal and Liver Physiology, ISSN 0193-1857, E-ISSN 1522-1547, Vol. 310, no 5, G303-G309 p.Article in journal (Refereed) Published
Abstract [en]

Acute pancreatitis is an inflammatory condition that may lead to multisystemic organ failure with considerable mortality. Recently, resolvin D1 (RvD1) as an endogenous anti-inflammatory lipid mediator has been confirmed to protect against many inflammatory diseases. This study was designed to investigate the effects of RvD1 in acute pancreatitis and associated lung injury. Acute pancreatitis varying from mild to severe was induced by cerulein or cerulein combined with LPS, respectively. Mice were pretreated with RvD1 at a dose of 300 ng/mouse 30 min before the first injection of cerulein. Severity of AP was assessed by biochemical markers and histology. Serum cytokines and myeloperoxidase (MPO) levels in pancreas and lung were determined for assessing the extent of inflammatory response. NF-kappa B activation was determined by Western blotting. The injection of cerulein or cerulein combined with LPS resulted in local injury in the pancreas and corresponding systemic inflammatory changes with pronounced severity in the cerulein and LPS group. Pretreated RvD1 significantly reduced the degree of amylase, lipase, TNF-alpha, and IL-6 serum levels; the MPO activities in the pancreas and the lungs; the pancreatic NF-kappa B activation; and the severity of pancreatic injury and associated lung injury, especially in the severe acute pancreatitis model. These results suggest that RvD1 is capable of improving injury of pancreas and lung and exerting anti-inflammatory effects through the inhibition of NF-kappa B activation in experimental acute pancreatitis, with more notable protective effect in severe acute pancreatitis. These findings indicate that RvD1 may constitute a novel therapeutic strategy in the management of severe acute pancreatitis.

Place, publisher, year, edition, pages
AMER PHYSIOLOGICAL SOC, 2016
Keyword
acute pancreatitis; resolvin D1; inflammation; nuclear factor-kappa B; lung injury
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-126827 (URN)10.1152/ajpgi.00355.2014 (DOI)000371303400002 ()26702138 (PubMedID)
Note

Funding Agencies|National Natural Science Fund of China (NSFC key project) [30830100, 81170439, 81470886, 81500486]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry [20101174-4-2]

Available from: 2016-04-07 Created: 2016-04-05 Last updated: 2017-11-30
Vernmark, K., Albertsson, M., Björnsson, B., Gasslander, T., Sandström, P., Sun, X.-F. & Holmqvist, A. (2015). From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report. BMC Cancer, 15(884).
Open this publication in new window or tab >>From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report
Show others...
2015 (English)In: BMC Cancer, ISSN 1471-2407, E-ISSN 1471-2407, Vol. 15, no 884Article in journal (Refereed) Published
Abstract [en]

Background: Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is associated with poorer response to chemotherapy and chemoradiotherapy. Case presentation: A 27-year-old Swedish woman presented with stomach pain and weight loss, and was diagnosed with locally advanced MAC in the transverse colon as well as 3 liver metastases. Neoadjuvant treatment with fluorouracil, folinic acid and oxaliplatin (FLOX) failed due to several infections, pulmonary embolism and deteriorated performance status. The patient was therefore considered palliative. Palliative treatment with metronomic capecitabine 500 mg x 2 daily and bevacizumab every other week were initiated. After 4 months of treatment the tumors had regressed and the patient was able to undergo radical surgery, thereby changing the treatment intention from palliative to curative. No adjuvant chemotherapy was given. There were no signs of recurrence 9 months later. Conclusions: The role of the combination of metronomic capecitabine and bevacizumab in patients with MAC merits further investigation.

Place, publisher, year, edition, pages
BIOMED CENTRAL LTD, 2015
Keyword
Mucinous adenocarcinoma; Bevaczumab; Metronomic capecitabine
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-123523 (URN)10.1186/s12885-015-1908-3 (DOI)000365272200003 ()26555668 (PubMedID)
Note

Funding Agencies|foundation of Oncological Clinical Research in Linkoping

Available from: 2015-12-22 Created: 2015-12-21 Last updated: 2017-12-01
Wang, M.-J., Wang, Z.-Q., Wang, R., Ping, J., Zhou, Z.-G. & Sun, X.-F. (2015). Letter: The elderly patients with colorectal cancer need careful multidisciplinary evaluation and optimizing comprehensive management in INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol 30, issue 5, pp 713-714 [Letter to the editor]. International Journal of Colorectal Disease, 30(5), 713-714.
Open this publication in new window or tab >>Letter: The elderly patients with colorectal cancer need careful multidisciplinary evaluation and optimizing comprehensive management in INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol 30, issue 5, pp 713-714
Show others...
2015 (English)In: International Journal of Colorectal Disease, ISSN 0179-1958, E-ISSN 1432-1262, Vol. 30, no 5, 713-714 p.Article in journal, Letter (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Springer Verlag (Germany), 2015
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-118041 (URN)10.1007/s00384-014-2036-2 (DOI)000353348800021 ()25336304 (PubMedID)
Available from: 2015-05-21 Created: 2015-05-20 Last updated: 2017-12-04
Meng, W.-J., Yang, L., Ma, Q., Zhang, H., Adell, G., Arbman, G., . . . Sun, X.-F. (2015). MicroRNA Expression Profile Reveals miR-17-92 and miR-143-145 Cluster in Synchronous Colorectal Cancer. Medicine (Baltimore, Md.), 94(32).
Open this publication in new window or tab >>MicroRNA Expression Profile Reveals miR-17-92 and miR-143-145 Cluster in Synchronous Colorectal Cancer
Show others...
2015 (English)In: Medicine (Baltimore, Md.), ISSN 0025-7974, E-ISSN 1536-5964, Vol. 94, no 32Article in journal (Refereed) Published
Abstract [en]

The expression of abnormal microRNA (miRNA, miR) is a ubiquitous feature of colorectal cancer (CRC). The pathological features and clinical behaviors of synchronous CRC have been comprehensively described; however, the expression profile of miRNA and small nucleolar RNA (snoRNA) in synchronous CRC has not been elucidated. In the present study, the expression profile of miRNA and snoRNA in 5 synchronous CRCs, along with the matched normal colorectal tissue was evaluated by microarray. Function and pathway analyses of putative targets, predicted from miRNA-mRNA interaction, were performed. Moreover, we analyzed clinicopathological and molecular characteristics of 22 patients with synchronous CRC and 579 solitary CRCs in a retrospective cohort study. We found a global dysregulation of miRNAs, including an oncogenic miR-17-92 cluster and oncosuppressive miR-143-145 cluster, and snoRNAs in synchronous CRC. Differential miRNA rather than snoRNA expression was robust enough to distinguish synchronous cancer from normal mucosa. Function analysis of putative targets suggested that miRNA clusters may modulate multiple effectors of oncogenic pathways involved in the pathogenesis of synchronous CRC. A comparison of normal mucosa between synchronous and solitary CRC suggested a differential genetic background of synchronous CRC from solitary CRC during carcinogenesis. Compared with solitary cancer patients, synchronous cases exhibited multiple extra-colonic cancers (P=0.012), coexistence of adenoma (P=0.012), microsatellite instability (P=0.024), and less glucose transporter 1 (P=0.037). Aberrant miRNA expression profiles could potentially be used as a diagnostic tool for synchronous CRC. Our findings represent the first comprehensive miRNA and snoRNA expression signatures for synchronous CRC, implicating that the miRNAs and snoRNAs may present therapeutic targets for synchronous CRC.

Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS and WILKINS, 2015
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-122220 (URN)10.1097/MD.0000000000001297 (DOI)000362203600001 ()26266366 (PubMedID)
Note

Funding Agencies|Swedish Cancer Foundation; Swedish Research Council; Health Research Council in the South-East of Sweden

Available from: 2015-10-26 Created: 2015-10-23 Last updated: 2017-12-01
Wang, M.-J., Ping, J., Li, Y., Holmqvist, A., Adell, G., Arbman, G., . . . Sun, X.-F. (2015). Prognostic Significance and Molecular Features of Colorectal Mucinous Adenocarcinomas: A Strobe-Compliant Study. Medicine (Baltimore, Md.), 94(51), e2350.
Open this publication in new window or tab >>Prognostic Significance and Molecular Features of Colorectal Mucinous Adenocarcinomas: A Strobe-Compliant Study
Show others...
2015 (English)In: Medicine (Baltimore, Md.), ISSN 0025-7974, E-ISSN 1536-5964, Vol. 94, no 51, e2350- p.Article in journal (Refereed) Published
Abstract [en]

Mucinous adenocarcinoma (MC) is a special histology subtype of colorectal adenocarcinoma. The survival of MC is controversial and the prognostic biomarkers of MC remain unclear. To analyze prognostic significance and molecular features of colorectal MC. This study included 755,682 and 1001 colorectal cancer (CRC) patients from Surveillance, Epidemiology, and End Results program (SEER, 1973 2011), and Linkoping Cancer (LC, 1972-2009) databases. We investigated independently the clinicopathological characteristics, survival, and variety of molecular features from these 2 databases. MC was found in 9.3% and 9.8% patients in SEER and LC, respectively. MC was more frequently localized in the right colon compared with nonmucinous adenocarcinoma (NMC) in both SEER (57.7% vs 37.2%, P < 0.001) and LC (46.9% vs 27.7%, P < 0.001). Colorectal MC patients had significantly worse cancer-specific survival (CSS) than NMC patients (SEER, P < 0.001; LC, P = 0.026), prominently in stage III (SEER, P < 0.001; P=0.023). The multivariate survival analysis showed that MC was independently related to poor prognosis in rectal cancer patients (SEER, hazard ratios [HR], 1.076; 95% confidence intervals [CI], 1.057-1.096; P < 0.001). In LC, the integrated analysis of genetic and epigenetic features showed that that strong expression of PINCH (HR, 3.954; 95% CI, 1.493-10.47; P = 0.013) and weak expression of RAD50 (HR 0.348, 95% CT, 0.106-1.192; P=0.026) were significantly associated with poor CSS of colorectal MC patients. In conclusion, the colorectal MC patients had significantly worse CSS than NMC patients, prominently in stage III. MC was an independent prognostic factor associated with worse survival in rectal cancer patients. The PINCH and RAD50 were prognostic biomarkers for colorectal MC patients.

Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS, 2015
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-125839 (URN)10.1097/MD.0000000000002350 (DOI)000369856200034 ()26705231 (PubMedID)
Note

Funding Agencies|National Scientific Foundation of China [81401949, 81300359]; Swedish Cancer Foundation; Swedish Research Council; Health Research Council in the South-East of Sweden

Available from: 2016-03-08 Created: 2016-03-04 Last updated: 2017-11-30
Pathak, S., Meng, W.-J., Kumar Nandy, S., Ping, J., Bisgin, A., Helmfors, L., . . . Sun, X.-F. (2015). Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner. OncoTarget, 6(42), 44758-44780.
Open this publication in new window or tab >>Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner
Show others...
2015 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 6, no 42, 44758-44780 p.Article in journal (Refereed) Published
Abstract [en]

Aberrant expression of miRNAs, cytokines and chemokines are involved in pathogenesis of colon cancer. However, the expression of p53 mediated miRNAs, cyto- and chemokines after radiation and SN38 treatment in colon cancer remains elusive. Here, human colon cancer cells, HCT116 with wild-type, heterozygous and a functionally null p53, were treated by radiation and SN38. The expression of 384 miRNAs was determined by using the TaqMan (R) miRNA array, and the expression of cyto- and chemokines was analyzed by Meso-Scale-Discovery instrument. Up- or down-regulations of miRNAs after radiation and SN38 treatments were largely dependent on p53 status of the cells. Cytokines, IL-6, TNF-alpha, IL-1 beta, Il-4, IL-10, VEGF, and chemokines, IL-8, MIP-1 alpha were increased, and IFN-gamma expression was decreased after radiation, whereas, IL-6, IFN-gamma, TNF-alpha, IL-1 beta, Il-4, IL-10, IL-8 were decreased, and VEGF and MIP-1 alpha were increased after SN38 treatment. Bioinformatic analysis pointed out that the highly up-regulated miRNAs, let-7f-5p, miR-455-3p, miR-98, miR-155-5p and the down-regulated miRNAs, miR-1, miR-127-5p, miR-142-5p, miR-202-5p were associated with colon cancer pathways and correlated with cyto- or chemokine expression. These miRNAs have the potential for use in colon cancer therapy as they are related to p53, pro- or anti-inflammatory cyto- or chemokines after the radiation and SN38 treatment.

Place, publisher, year, edition, pages
IMPACT JOURNALS LLC, 2015
Keyword
colon cancer cells; p53; miRNAs; cytokines; chemokines
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-125835 (URN)10.18632/oncotarget.5815 (DOI)000369908800052 ()26556872 (PubMedID)
Note

Funding Agencies|Swedish Cancer Foundation; Swedish Research Council; Health Research Council in the South-East of Sweden

Available from: 2016-03-08 Created: 2016-03-04 Last updated: 2017-11-30
Bruun, J., Kolberg, M., Ahlquist, T. C., Royrvik, E. C., Nome, T., Leithe, E., . . . Lothe, R. A. (2015). Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer. Clinical Cancer Research, 21(16), 3759-3770.
Open this publication in new window or tab >>Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer
Show others...
2015 (English)In: Clinical Cancer Research, ISSN 1078-0432, E-ISSN 1557-3265, Vol. 21, no 16, 3759-3770 p.Article in journal (Refereed) Published
Abstract [en]

Purpose: Colorectal cancer has high incidence and mortality worldwide. Patients with microsatellite instable (MSI) tumors have significantly better prognosis than patients with microsatellite stable (MSS) tumors. Considerable variation in disease outcome remains a challenge within each subgroup, and our purpose was to identify biomarkers that improve prediction of colorectal cancer prognosis. Experimental Design: Mutation analyses of 42 MSI target genes were performed in two independent MSI tumor series (n = 209). Markers that were significantly associated with prognosis in the test series were assessed in the validation series, followed by functional and genetic explorations. The clinical potential was further investigated by immunohistochemistry in a population-based colorectal cancer series (n = 903). Results: We identified the cell-cycle gene regulator of chromosome condensation 2 (RCC2) as a cancer biomarker. We found a mutation in the 50 UTR region of RCC2 that in univariate and multivariate analyses was significantly associated with improved outcome in the MSI group. This mutation caused reduction of protein expression in dual luciferase gene reporter assays. siRNA knockdown in MSI colon cancer cells (HCT15) caused reduced cell proliferation, cell-cycle arrest, and increased apoptosis. Massive parallel sequencing revealed few RCC2 mutations in MSS tumors. However, weak RCC2 protein expression was significantly associated with poor prognosis, independent of clinical highrisk parameters, and stratifies clinically important patient subgroups with MSS tumors, including elderly patients (greater than 75 years), stage II patients, and those with rectal cancer. Conclusions: Impaired RCC2 affects functional and clinical endpoints of colorectal cancer. High-risk patients with either MSI or MSS tumors can be identified with cost-effective routine RCC2 assays. (C) 2015 AACR.

Place, publisher, year, edition, pages
AMER ASSOC CANCER RESEARCH, 2015
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-122121 (URN)10.1158/1078-0432.CCR-14-3294 (DOI)000361909100024 ()25910952 (PubMedID)
Note

Funding Agencies|Norwegian Cancer Society [PR-2006-0442, PR-2007-0166]; South-Eastern Norway Regional Health Authority

Available from: 2015-10-19 Created: 2015-10-19 Last updated: 2017-12-01
Organisations

Search in DiVA

Show all publications